Sign in

KZIA on Nasdaq

KAZIA THERAPEUTICS LTD

Pharmaceutical preparations company based in Sydney Nsw1

In its 2025 annual report (Form 20-F) the company says: “The Company is an emerging oncology-focused biotechnology company that has a portfolio of development candidates, diversified across several distinct technologies, with the potential to yield first-in-class and best-in-class agents in a range of oncology indications.”4 Its shares trade on Nasdaq under the symbol KZIA.1

Price unavailable

Last updated Oct 21, 2026.

Overview

42.0KRevenue, fiscal 20252
-20.7MNet income, fiscal 20252

Compare with ALTERITY THERAPEUTICS LTD or Immutep, or pick any stock.

  • TickerKZIA on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersC31
  • Incorporated inAustralia3
  • Business addressThree International Towers Level 24,, 300 Barangaroo Avenue, Sydney Nsw, 20003
  • Filer categoryNon-accelerated filer3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Kazia Therapeutics Limited (“Kazia” or the “Company”), a public company limited by shares, was incorporated in March 1994 and registered in New South Wales, Australia. Kazia is registered and operates under the Corporations Act.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in AUD, the currency the company reports in.

Key numbers, fiscal 2025

-49290.5%Net margin2
-98.2%Revenue growth, 20252

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development41¢7.3M AUD
  • Selling, general and admin49¢8.7M AUD
  • Income tax10¢1.7M AUD

Out of 42.0K AUD in revenue.2 The company lost money this year.

Financial statements

Revenue5242.0K AUD in 2025−65% since 2018
01.0M AUD2.0M AUD3.0M AUD2018: 119.0K AUD119.0K AUD20182023: 0 AUD0 AUD20232024: 2.3M AUD2.3M AUD20242025: 42.0K AUD42.0K AUD2025−98%
Net income6789102-20.7M AUD in 2025+243% since 2018
-30.0M AUD-20.0M AUD-10.0M AUD02018: -6.0M AUD-6.0M AUD20182019: -10.3M AUD-10.3M AUD2019+70%2020: -12.5M AUD-12.5M AUD2020+21%2021: -8.4M AUD-8.4M AUD2021−32%2022: -25.0M AUD-25.0M AUD2022+197%2023: -20.5M AUD-20.5M AUD2023−18%2024: -26.8M AUD-26.8M AUD2024+31%2025: -20.7M AUD-20.7M AUD2025−23%

Every line of the income statement as filed: the last 3 fiscal years, latest first.2

Period ending2025-06-302024-06-302023-06-30
Revenue42.0K AUD2.3M AUD0 AUD
Other income1.8M AUD173.0K AUD1.0K AUD
Finance income72.0K AUD12.0K AUD22.0K AUD
Research and development expense-7.3M AUD-17.4M AUD-15.6M AUD
General and administrative expense-8.7M AUD-13.6M AUD-8.6M AUD
Impairment of intangible assets-13.4M AUD0 AUD0 AUD
(Loss) gain on remeasurement of other financial liabilities-2.5M AUD1.3M AUD0 AUD
Gain on remeasurement of promissory note0 AUD25.0K AUD0 AUD
Gain on remeasurement of contingent consideration7.6M AUD119.0K AUD3.4M AUD
Loss before income tax benefit-22.4M AUD-27.0M AUD-20.7M AUD
Income tax benefit1.7M AUD271.0K AUD271.0K AUD
Loss after income tax benefit-20.7M AUD-26.8M AUD-20.5M AUD
Net exchange difference on translation of financial statements of foreign controlled entities, net of tax-23.0K AUD-8.0K AUD110.0K AUD
Other comprehensive income (loss), net of tax-23.0K AUD-8.0K AUD110.0K AUD
Total comprehensive income/(loss)-20.7M AUD-26.8M AUD-20.4M AUD
Basic earnings per share-0.04 AUD-0.10 AUD-0.11 AUD
Diluted earnings per share-0.04 AUD-0.10 AUD-0.11 AUD

Compare KAZIA THERAPEUTICS LTD with another company

Corporate structure

KAZIA THERAPEUTICS LTD sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of KAZIA THERAPEUTICS LTD

  • Dauntless Investment Group, LLC Filed SCHEDULE 13G/A on KAZIA THERAPEUTICS LTD, latest Oct 2, 2026 (5 filings since Jun 13, 2025)
  • Jorey Chernett Filed SCHEDULE 13G/A on KAZIA THERAPEUTICS LTD, latest Aug 19, 2026 (5 filings since Jun 12, 2025)
  • Ikarian Capital, LLC Filed SCHEDULE 13G/A on KAZIA THERAPEUTICS LTD, latest Aug 14, 2026 (2 filings since Feb 17, 2026)
  • Lynwood Capital Management Inc. Filed SCHEDULE 13G/A on KAZIA THERAPEUTICS LTD, latest Aug 14, 2026 (2 filings since Jan 23, 2026)
  • Alumni Capital LP Filed SCHEDULE 13G/A on KAZIA THERAPEUTICS LTD, latest Mar 30, 2026 (6 filings since Jul 2, 2024)
  • ARMISTICE CAPITAL, LLC Filed SC 13G/A on KAZIA THERAPEUTICS LTD, latest Nov 14, 2024 (2 filings since Feb 14, 2024)
  • PLATINUM INVESTMENT MANAGEMENT LTD Filed SC 13G on KAZIA THERAPEUTICS LTD, latest Nov 6, 2024 (2 filings since Feb 12, 2024)
  • KAZIA THERAPEUTICS LTD C3

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What KAZIA THERAPEUTICS LTD reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents4.3M AUD2 Jun 30, 20251.7M AUD2 Jun 30, 2024+162.2%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)1.1M AUD2 Jun 30, 202515.4M AUD2 Jun 30, 2024−92.9%

Leadership

Who has led KAZIA THERAPEUTICS LTD, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. John E. Friend Ii.2026–now

Chief financial officer

  1. James E. Levine2026–now
2010201520202025
Board members and other officers (8)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerElissa Hansen named Jan 17, 2025 to Dec 18, 202521
  • Executive OfficerKaren Krumeich named Dec 15, 202322
  • DirectorBryce Carmine named Dec 15, 2023 to Dec 18, 202521

Former names

  • NOVOGEN LTDMar 6, 2002 to Nov 17, 20173

Timeline

  1. Mar 18, 2026New chief executive John E. Friend Ii. becomes CEO11

Filings

370 filings to the SEC since October 2021: 5 annual reports, 18 insider forms, 24 large holders, 4 private raises, 319 other. The latest 20:

  1. Oct 2, 2026SCHEDULE 13G/A EDGAR
  2. Sep 22, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
  3. Sep 22, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
  4. Sep 22, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
  5. Sep 22, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
  6. Sep 22, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  7. Sep 18, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
  8. Sep 18, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
  9. Sep 18, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
  10. Sep 18, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
  11. Sep 18, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  12. Sep 1, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
  13. Sep 1, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
  14. Sep 1, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
  15. Sep 1, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
  16. Sep 1, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  17. Aug 31, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
  18. Aug 31, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
  19. Aug 31, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
  20. Aug 31, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR

The 370 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$61.4M 2023–2025
Money received by yearMoney received by year, 2023–2025: $61.4M in all. Private raises (Form D) $61.4M.$0$20M$40M$60M2023 · Private raises (Form D): $2.0M202320242025 · Private raises (Form D): $59.4M2025
Figures by year
YearPrivate raises (Form D)Total
2025$59.4M$59.4M
2023$2.0M$2.0M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Dec 3, 2025Raised $55.3 million in a private offering of equity21 Form D: 65 investors so far Form D
  2. Aug 4, 2025Raised $2.1 million in a private offering of equity30 Form D: 4 investors so far Form D
  3. Jan 10, 2025Raised $2.1 million in a private offering of securities31 Form D: 1 investor so far Form D
  4. Dec 5, 2023Raised $2 million in a private offering of securities22 Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 36. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Boxer Capital Management, LLC560,000$7.9M0.6%New
Flputnam Investment Management Co414,958$5.8M0.1%+272,489
Bleichroeder LP400,000$5.6M1.0%No change
Ikarian Capital, LLC396,201$5.6M0.9%New
Dauntless Investment Group, LLC354,208$5.0M8.6%+274,376
Stonepine Capital Management, LLC345,179$4.9M3.7%No change
Point72 Asset Management, L.P.200,300$2.3M0.0%+300
Ensign Peak Advisors, Inc110,778$1.6M0.0%New
Millennium Management LLC101,376$1.4M0.0%New
UBS Group AG81,090$1.1M0.0%+67,156
J. Goldman & Co LP68,491$964.4K0.0%New
ADAR1 Capital Management, LLC61,550$866.6K0.0%New
Jane Street Group, LLC57,140$804.5K0.0%New
Barclays PLC56,999$802.5K0.0%+33,000
Susquehanna International Group, Llp50,616$712.7K0.0%New
Cooperman Leon G50,000$704.0K0.0%New
Westside Investment Management, Inc.47,585$670.0K0.1%−2,840
Morgan Stanley46,606$656.2K0.0%+45,606
Marshall Wace, Llp44,231$622.8K0.0%New
XTX Topco Ltd31,186$439.1K0.0%New
Bnp Paribas Financial Markets30,090$423.7K0.0%+29,009
Citadel Advisors LLC28,509$401.4K0.0%New
Raymond James Financial Inc22,599$318.2K0.0%+6,850
Sequoia Financial Advisors, LLC20,003$281.6K0.0%−39,997
Engineers Gate Manager LP14,975$210.8K0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How KAZIA THERAPEUTICS LTD is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARKAZIA THERAPEUTICS LTD1
  • CIK0001075880
  • Filer statusNon-accelerated filer not an emerging growth company; not a shell company4
  • Incorporated inAustralia4
  • Fiscal year endsJune 301
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressThree International Towers Level 24,, 300 Barangaroo Avenue, Sydney Nsw, 2000, Australia1
  • Phone011612987800881
  • Shares outstanding809,418,734 shares as of Jun 30, 20254
  • AuditorBDO Audit Pty Ltd, Sydney, Australia PCAOB ID 2256; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceFeb 1, 20021
  • Filings1,190 in all: 6-K (759), 424B3 (145), 4 (72), CORRESP (27), UPLOAD (25), 20-F (24), SC 13D/A (20), EFFECT (17)1
    All 29 form types

    SCHEDULE 13G/A (13), 3 (11), 424B5 (9), SC 13G (8), 20-F/A (7), F-3 (7), SC 13G/A (7), F-1 (6), SCHEDULE 13G (5), 6-K/A (4), D (4), POS AM (4), F-3/A (3), NT 20-F (3), 424B1 (2), CT ORDER (2), SC 13D (2), 10-Q (1), 3/A (1), F-1/A (1), F-6 (1)

  • Latest filingsAnnual report (20-F) Nov 7, 2025
    Quarterly report (10-Q) Nov 7, 2006

Securities registered for trading

ClassSymbolExchange
American Depositary Shares, each representing five-hundred Ordinary Shares*KZIANasdaq

From the cover page of the 20-F filed Nov 7, 2025 (Section 12(b) of the Exchange Act).4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31